CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 6 enrolled
Drug / intervention
Olaparib +1 moredrug
Likely dose
Olaparib 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05203445
NCT05203445Phase 2Active
CompareCT.gov

Phase II of Neoadjuvant Olaparib in Combination With Pembrolizumab in Patients With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer and Germline Mutations in DNA Damage Repair Genes

Memorial Sloan Kettering Cancer Center·interventional·Posted Jan 24, 2022·Updated May 29, 2026

In Brief

A Phase 2 clinical trial evaluating Olaparib and Pembrolizumab for Breast Cancer. Active but no longer recruiting, targeting 6 participants across 7 sites.

Detailed Summary

This study will test any good and bad effects of combining the study drugs pembrolizumab and olaparib, given before the standard surgical procedure, to treat TNBC or HR+ HER2- breast cancers. The study drugs could shrink cancer, but they could also cause side effects. The study researchers want to find out whether the study drugs will shrink the cancer by a certain percentage compared with its current size, which may improve the outcome of surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2Active
202220232024202520262027
First PostedJan 24, 2022
Enrollment StartJan 31, 2022
Primary CompletionMay 29, 2025
Study CompletionJan 1, 2027
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 4.4 years ago

Interventions

Olaparibdrug

Olaparib 300 mg orally BID

Pembrolizumabdrug

Pembrolizumab 400 mg intravenously q6weeks